Cargando…
Cucurbitacin B enhances apoptosis in gefitinib resistant non-small cell lung cancer by modulating the miR-17-5p/STAT3 axis
Tyrosine kinase inhibitors, such as gefitinib, are currently widely used as targeted therapeutics for non-small cell lung cancer (NSCLC). Although drug resistance has become a major obstacle to successful treatment, mechanisms underlying resistance to gefitinib remain unclear. Therefore, the present...
Autores principales: | Yu, Baodan, Zheng, Lixia, Tang, Huiqin, Wang, Weixin, Lin, Yongping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383048/ https://www.ncbi.nlm.nih.gov/pubmed/34396444 http://dx.doi.org/10.3892/mmr.2021.12349 |
Ejemplares similares
-
Cucurbitacin B regulates lung cancer cell proliferation and apoptosis via inhibiting the IL-6/STAT3 pathway through the lncRNA XIST/miR-let-7c axis
por: Liu, Jian-Hua, et al.
Publicado: (2021) -
let-7 and miR-17 promote self-renewal and drive gefitinib resistance in non-small cell lung cancer
por: Yin, Jun, et al.
Publicado: (2019) -
Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells
por: Brouwer, Isabella J., et al.
Publicado: (2020) -
miR-155 Regulated Inflammation Response by the SOCS1-STAT3-PDCD4 Axis in Atherogenesis
por: Ye, Jinshan, et al.
Publicado: (2016) -
Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)